ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Celgene strikes second deal with Skyhawk

by Ryan Cross
November 17, 2019 | APPEARED IN VOLUME 97, ISSUE 45

 

In June 2018, Celgene announced a $60 million partnership with Skyhawk Therapeutics to develop small-molecule drugs that alter RNA splicing. The pharma firm is striking a second deal with Skyhawk, worth $80 million up front, to develop small molecules for traditionally undruggable targets in autoimmune diseases, cancer, and immuno-oncology. The first partnership, which is ongoing, focuses on neurological diseases such as amyotrophic lateral sclerosis and Huntington’s disease. Skyhawk is one of C&EN’s 10 Start-Ups to Watch this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment